Source: International Congress 2016 – Asthma: treatment, disease control, and quality of life
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Hana Müllerová (Uxbridge, Middlesex, United Kingdom), Frank Albers, Sarah Cockle, Necdet Gunsoy, Ji-Yeon Shin, Linda Nelsen, Hana Muellerova. Eligibility for mepolizumab, omalizumab and reslizumab in the EU population: The IDEAL study. Eur Respir J 2016; 48: Suppl. 60, 4216

Member's Comments

No comment yet.

Related content which might interest you: Asthma control using fluticasone propionate/salmeterol: GOAL study re-analysis using GINA 2016 guidelines Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Fluticasone propionate/formoterol therapy for asthmatic patients: Results of a non-interventional study Source: International Congress 2016 – Asthma management Year: 2016 Asthma control is reached in a large majority of asthmatics treated with omalizumab. An Italian observational study Source: Annual Congress 2013 –Disease control and quality of life in airway diseases Year: 2013 A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Omalizumab in allergic eosinophilic asthma and lung eosinophil numbers: A 78-week randomized controlled trial Source: Annual Congress 2013 –Treatment of asthma Year: 2013 P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016 Clinical and economic outcomes following 52-week add-on omalizumab Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study. Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Evaluation of roflumilast in COPD patients in a real-world European setting: results from the PROFILE EU study Source: International Congress 2017 – What is new in COPD management and prognosis: findings from large studies? Year: 2017 Characteristics of severe asthmatics treated with omalizumab, mepolizumab or no biotherapy. Data from the Belgian Severe Asthma Registry (BSAR). Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases Year: 2019 Safety and effectiveness of indacaterol in Korean COPD patients: A post-marketing surveillance (PMS) study Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Late Breaking Abstract - International, prospective real-world study of mepolizumab in patients with severe asthma at one year: REALITI-A Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Effectiveness of omalizumab in Greek patients with severe allergic asthma (SAA): The SMILE study Source: International Congress 2016 – Asthma points to ponder Year: 2016 Interim analysis of a prospective study investigating oral corticosteroid (OCS) use in omalizumab treated severe allergic asthma patients: APEX II study Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Asthma control in asthmatics treated with extrafine or non-extrafine ICS/LABA combinations in real life setting Source: Annual Congress 2013 –Diagnosis and management of respiratory diseases Year: 2013 APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015 Impact of adherence to fluticasone propionate/salmeterol combination (FSC) therapy on the outcomes of patients with asthma: A population based study Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level Source: Annual Congress 2013 –Treatment of asthma Year: 2013 X-Tab: Non-interventional study to assess patient-related mid-term outcomes of omalizumab therapy in severe allergic asthmatic patients Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016 Long-term (5 year) safety of bronchial thermoplasty in patients with moderate to severe asthma: Asthma Intervention Research (AIR) Trial Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010